Volume 19 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(3): 379-382,453
WANG Gui-feng, CUI Zhen, WAN Qiang-kun, JIANG Hao. Observation of curative effect and analysis of prognostic factors of S-1 adjuvant chemotherapy after radical concurrent chemoradiotherapy for esophageal squamous cell carcinoma in the elderly[J]. Chinese Journal of General Practice, 2021, 19(3): 379-382,453. doi: 10.16766/j.cnki.issn.1674-4152.001815
Citation: WANG Gui-feng, CUI Zhen, WAN Qiang-kun, JIANG Hao. Observation of curative effect and analysis of prognostic factors of S-1 adjuvant chemotherapy after radical concurrent chemoradiotherapy for esophageal squamous cell carcinoma in the elderly[J]. Chinese Journal of General Practice, 2021, 19(3): 379-382,453. doi: 10.16766/j.cnki.issn.1674-4152.001815
shu

Observation of curative effect and analysis of prognostic factors of S-1 adjuvant chemotherapy after radical concurrent chemoradiotherapy for esophageal squamous cell carcinoma in the elderly

doi: 10.16766/j.cnki.issn.1674-4152.001815

  • Department of Radiotherapy, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0357

 卫科教2018-291

  • Received Date: 2020-08-07
    Available Online: 2022-02-19
    Abstract
  •   Objective  To analyze the clinical efficacy and prognostic factors of the elderly patients with esophageal squamous cell carcinoma who underwent radical concurrent chemoradiotherapy (CCRT) followed by S-1 adjuvant chemotherapy.  Methods  A total of 102 elderly patients with esophageal squamous cell carcinoma (≥ 70 years old) were enrolled in this study from June 1, 2016 to June 30, 2019. All the patients had received radical concurrent chemoradiotherapy in the Radiotherapy Department of the First Affiliated Hospital of Bengbu Medical College. The patients were divided into chemotherapy group (42 cases) and control group (60 cases) according to whether or not they received S-1 adjuvant chemotherapy. Kaplan-Meier statistical analysis was conducted for T staging, adjuvant chemotherapy and length of primary tumor (GTV length).  Results  The 2-year and 3-year overall survival rates (OS) in the chemotherapy group and the control group were 54.1%, 42.6% and 38.4%, 28.5% (P=0.081), the 2-year and 3-year progression free survival rates (PFS) were 55.4%, 44.3% and 32.9%, 21.8% (P=0.024), and the 2-year and 3-year local recurrence free survival rates (LRFFS) were 68.2%, 61.4% and 39.2%, 25.9% (P=0.004), respectively. Cox model multivariate analysis showed that adjuvant chemotherapy had better PFS and LRFFS (all P < 0.05). Clinical stage Ⅱ-Ⅲ had better OS, PFS and LRFFS than stage Ⅳ. lymph node status (N status) was closely related to OS and PFS. Age was an independent predictor of OS.  Conclusion  For elderly patients with esophageal squamous cell carcinoma, after concurrent chemoradiotherapy, S-1 adjuvant chemotherapy can improve PFS and LRFFS, and the incidence of related adverse reactions is low and can be tolerated.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
    [2]
    CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
    [3]
    UEDA S, KAWAKAMI H, NISHINA S, et al. Phase Ⅰ trial of 5-FU, docetaxel, and nedaplatin(UDON) combination therapy for recurrent or metastatic esophageal cancer[J]. Cancer Chemoth Pharm, 2015, 76(2): 279-285. doi: 10.1007/s00280-015-2799-3
    [4]
    UEDA H, KAWAKAMI H, NONAGASE Y, et al. Phase Ⅱ trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer[J]. Oncologist, 2019, 24(2): 163-176. doi: 10.1634/theoncologist.2018-0653
    [5]
    MBOUMI I W, REDDY S, LIDOR A O. Complications after esophagectomy[J]. Surg Clin North Am, 2019, 99(3): 501-510. doi: 10.1016/j.suc.2019.02.011
    [6]
    GUO J H, CHEN M Q, CHEN C, et al. Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma[J]. Mol Clin Oncol, 2015, 3(5): 1135-1138. doi: 10.3892/mco.2015.606
    [7]
    FAIZ Z, VAN PUTTEN M, VERHOEVEN R H A, et al. Impact of age and comorbidity on choice and outcome of two different treatment options for patients with potentially curable esophageal cancer[J]. Ann Surg Oncol, 2019, 26(4): 986-995. doi: 10.1245/s10434-019-07181-6
    [8]
    HERSKOVIC A, MARTZ K, AL-SARRAF M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J]. N Engl J Med, 1992, 326(24): 1593-1598. doi: 10.1056/NEJM199206113262403
    [9]
    ZHANG P, XI M, LI Q Q, et al. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis[J]. Oncotarget, 2016, 7(28): 44686-44694. doi: 10.18632/oncotarget.9301
    [10]
    MIAO Y, ZHAN P, LV T, et al. A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients[J]. Transl Lung Cancer Res, 2015, 4(4): 487-497. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549471/pdf/tlcr-04-04-487.pdf
    [11]
    ZHUANG Z X, ZHU H, WANG J, et al. Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients[J]. Acta Pharmacol Sin, 2013, 34(4): 570-580. doi: 10.1038/aps.2012.169
    [12]
    KASAI T, MORI K, KISHI K, et al. A phase Ⅰ and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101-[J]. Int J Clin Oncol, 2020, 25(24): 867-875.
    [13]
    CHEN J, WANG J. Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma[J]. Medicine, 2019, 98(23): e15999. doi: 10.1097/MD.0000000000015999
    [14]
    LI W, ZHAO X, WANG H, et al. Maintenance treatment of Uracil and Tegafur(UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase Ⅱ study[J]. Oncotarget, 2017, 8(23): 37826-37834. doi: 10.18632/oncotarget.13922
    [15]
    AKIYAMA N, KARAYAMA M, INUI N, et al. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma[J]. Invest New Drugs, 2019, 37(3): 531-537. doi: 10.1007/s10637-019-00747-x
    [16]
    SONG T, LV S, FANG M, et al. Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer[J]. Onco Targets Ther, 2016, 9: 5389-5397. doi: 10.2147/OTT.S107668
    [17]
    SHAPIRO J, VAN LANSCHOT J, HULSHOF M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090-1098. doi: 10.1016/S1470-2045(15)00040-6
    [18]
    VONCKEN F, VAN DER KAAIJ R T, SIKORSKA K, et al. Advanced age is not a contraindication for treatment with curative intent in esophageal cancer[J]. Am J Clin Oncol, 2018, 41(9): 919-926. doi: 10.1097/COC.0000000000000390
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (230) PDF downloads(9) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return